C12-TLRa

• Description :

  C12-TLRa is an ionized adjuvant lipid. C12-TLRa targets TLR7/8 receptors in endosomes. C12-TLRa enhances mRNA delivery as a structural component of LNPs. C12-TLRa enhances innate immune responses. C12-TLRa can be used for the research of SARS-CoV-2 mRNA vaccine[1][2].

• UNSPSC :

  12352005

• Target :

  Liposome; Toll-like Receptor (TLR)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/c12-tlra.html

• Purity :

  99.0

• Solubility :

  DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 50 mg/mL (ultrasonic)

• Smiles :

  NC1=NC2=CC=CC=C2C3=C1N=C(CCCC)N3CC4=CC=C(CN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)C=C4

• Molecular Formula :

  C46H73N5O2

• Molecular Weight :

  728.10

• References & Citations :

  [1]Han X, et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat Nanotechnol. 2023 Jun 26. |[2]Han EL, et al. Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain. Nano Lett. 2025 Jan 15;25 (2) :800-810.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  TLR7; TLR8

• CAS Number :

  [3067466-15-0]